Skip to main content

Table 2 Review of studies evaluating patients treated with cranial radiation and ipilimumab

From: Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review

  N Median overall survival (mos) Landmark survival Steroid use Timing issues Radiation necrosis requiring surgery
Kiess et al. [10] 46 12.4 1 yr OS 40–65 % depending on timing of ipi Routine use of ppx steroids SRS before or during ipi associated with improved OS 5 patients
Knisely et al. [19] 27 21.3 2 yr OS 47 % Not reported SRS before ipi associated with trend towards improved survival 3 patients
Mathew et al. [11] 25 5a 6 mos OS 56 % Routine use of ppx steroids Not reported 0
Schoenfeld et al. (current study) 16 14.4 1 yr OS 54 % No routine use of ppx steroids SRS before ipi associated with better survival 0
Shoukat et al. [20] 11 28.3 1 yr OS 67 % Not reported Not reported 3 patientsb
Tazi et al. [21] 10 29.3 2 yr OS 58 % Not reported All patients received SRS before or during ipi Not reported
  1. Abbreviations: mos months, ppx prophylactic, OS overall survival, ipi ipilimumab, SRS stereotactic radiosurgery
  2. aEstimated from survival curve
  3. bUse of surgery not specified